FDA CE-Marked Leverage Epigenomics’ established blood-based DNA methylation tests, including FDA-approved Epi proColon and CE-marked IVDs in Europe, to target oncology clinics and national screening programs seeking validated methylation-based cancer detection solutions.

Expansion Readiness Position opportunities around New Day Diagnostics’ ownership and the company’s recent leadership changes as a channel to accelerate adoption of Epigenomics’ Next-Gen colorectal screening and ongoing biomarker development across regions with evolving reimbursement landscapes.

IP and Partnerships Highlight the broad patent portfolio and collaboration potential for industry partners, research labs, and IVD developers to license methylation biomarkers or engage in co-development, creating multiple streams of revenue from partnerships and services.

Global Reach Target European and U.S. cancer screening networks, payer bodies, and hospital systems where CE IVDs and FDA-approved tests can be integrated into existing screening workflows, supported by Epigenomics’ multi-regional commercialization posture.

Financial Growth Exploit the company’s revenue trajectory and mid-sized employee base to propose scalable sales motions—integrated solutions for labs, biomarker services, and IVD development collaborations—while aligning with potential investors or acquirers seeking a growth-stage diagnostics play.